Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms

Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms

Pituitary neuroendocrine tumors (PitNET) are commonly benign tumors accounting for 10-25% of intracranial tumors. Prolactin-secreting adenomas represent the most predominant type of all PitNET and for this subtype of tumors, the medical therapy relies on the use of dopamine agonists (DAs). DAs yield...

ver descrição completa

Detalhes bibliográficos
Principais autores: Claudia Pivonello, Roberta Patalano, Mariarosaria Negri, Rosa Pirchio, Annamaria Colao, Rosario Pivonello, Renata Simona Auriemma
Formato: Artigo
Idioma:English
Publicado em: Frontiers Media S.A. 2022-01-01
coleção:Frontiers in Endocrinology
Assuntos:
dopamine
dopamine agonist
pituitary tumors
cabergoline
prolactinomas
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fendo.2021.791633/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2021.791633/full

Registros relacionados